Latest Earnings Results: Q3 '26
Estimated EPS
-$0.60
Reported EPS
$4.73
Surprise
+887.14%
Estimated Rev
$24.35M
Reported Rev
$673.06M
Surprise
+2664.31%
• Reported GAAP EPS of $4.73 up 559.22% YoY • Reported revenue of $673.06M up 8430.54% YoY • Nurix expects existing cash, cash equivalents and marketable securities of $1.1B to fund operations, including clinical trials and infrastructure, for at least the next 12 months; additional funding will be needed.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.41 | -- | -- | N/A |
Q3 '26 | -$0.60 | $4.73 | 887.14% | BEAT |
Q2 '26 | -$0.72 | -$0.81 | -12.05% | MISSED |
Q1 '26 | -$0.76 | -$0.79 | -3.60% | MISSED |
Q4 '25 | -$0.87 | -$0.82 | 5.85% | BEAT |